Add this topic to your myFT Digest for news straight to your inbox
Start-up secures first permit in more than 20 years for commercial cannabis cultivation
Lack of investment-grade companies and questions over legality run counter to optimism
The happy, hazy days of 2018 look a long way away
How to deal with social injustice via the magic of the capital markets, and Jay-Z.
Biotech bosses hail breakthrough as magic mushroom ingredient decriminalised in parts of US
Prime minister and a former leader backed the campaign to legalise pot
Further liberalisation would lift many constraints, including the ability of institutions to invest
Chrystal Capital hopes to profit from legalisation moves even though shares in sector have struggled
FCA guidance clears way for companies providing products for medical use to float on stock exchange
Companies warn current regulations will encourage investment to shift elsewhere in Europe
Silverpeak subsidiary aims to become world’s largest producer of medicinal marijuana by 2025
Magazine group buys outlets from one of America’s largest retail and wholesale marijuana distributors
Everyone from pet stores to cannabis growers are trying to avoid being closed during the coronavirus outbreak
US drug laws are complex, contradictory and affect black communities disproportionately
UK smallholders hope to cash in on the CBD oil craze, as regulations relax worldwide
A $10m fund for reparations to black residents of Evanston faces a struggle to be more than symbolic
Investors in a pioneering fund should brace themselves for a rollercoaster ride
Similar products in North America have proved popular despite a poor year for the sector
Insurers remain cautious in taking on risk, resulting in higher premiums
Momentum has stalled in key markets such as New York, New Jersey and Connecticut
Pot price falls and inventories grow as legal and illicit markets compete for customers
Promises of huge growth are yet to materialise — but there’s huge potential
Secret Buckinghamshire warehouse can store enough cannabis to supply 5,000 patients a month
Small issuers grab early mover advantage while others worry over legal risks
Some investors fear prosecution under anti-money laundering legislation
International Edition